ERBB2 and breast carcinoma: Although not FDA-approved as of the time of our analysis, and therefore excluded, our preliminary search included the CREATE-X trial of capecitabine in ERBB2 (formerly HER2)–negative breast cancer.19 Interestingly, capecitabine in the CREATE-X trial was excluded from our analysis because it was not FDA approved in the setting of breast cancer.